Collins Helen Louise

Kura Oncology, Inc. · Director

Collins Helen Louise is listed in filings as Director at Kura Oncology, Inc.. This profile follows SEC Form 4 activity through Jun 4, 2026, including sale activity. Recent filings connect the profile to Kura Oncology, Inc. (KURA), Enliven Therapeutics, Inc. (ELVN), and IO Biotech, Inc. (IOBT). The current snapshot covers public activity from Oct 22, 2024 to Jun 4, 2026. Reported amounts are shown as $306.9K to $52.4K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.

Latest Trades

CompanyValueActionPriceLast Price
Enliven Therapeutics, Inc.ELVN$137k3.5k sharesSellMay 18, 2026$39.53$53.20
Enliven Therapeutics, Inc.ELVN$52k1.3k sharesSellMay 18, 2026$40.25$53.20
Enliven Therapeutics, Inc.ELVN$9.2k223 sharesSellMay 18, 2026$41.21$53.20